Company news

Elanco Animal Health Incorporated (NYSE:ELAN) news

Elanco Animal Health Incorporated news releases on 6ix. Latest, Oct 6, 2026: Elanco Animal Health Incorporated : One Health Innovation District Breaks Ground…

Elanco Animal Health Incorporated (NYSE:ELAN) news

Press releases & updates

Elanco Animal Health Incorporated : One Health Innovation District Breaks Ground on One Health Research Institute, Anchored by Purdue University and Elanco Animal Health

Elanco to Participate in BofA Securities Global Healthcare Conference 2026

Expanding Tick and Itch Season Supports Momentum in Elanco Innovation, Meeting Pet Owner Demand for Health and Wellness Care

Elanco Confirms Date and Conference Call for Third Quarter 2026 Financial Results Announcement

Elanco to Participate in Morgan Stanley 24th Annual Global Healthcare Conference

Elanco Scales Biologics Capabilities With Expansion of Kansas Manufacturing Facility

Elanco Scales Biologics Capabilities with Expansion of Kansas Manufacturing Facility

Elanco's CLiK(TM) Extra (Dicyclanil Topical Suspension) Wound Spray Receives FDA Emergency Use Authorization for Application on or Around Wounds for Prevention of New World Screwworm in Variety of Livestock and Captive and Captured Wildlife Species

Elanco's CLiK™ Extra (dicyclanil topical suspension) Wound Spray Receives FDA Emergency Use Authorization for Application on or Around Wounds for Prevention of New World Screwworm in Variety of Livestock and Captive and Captured Wildlife Species

Elanco Animal Health Reports Second Quarter 2026 Results

Elanco Releases 2025 Impact Report, Demonstrating How Animal Health Helps Meet Society's Growing Needs

Credelio Quattro™ (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets) Kills Ticks¹ Faster² than Simparica Trio® (sarolaner, moxidectin, and pyrantel chewable tablets) and NexGard® Plus (afoxolaner, moxidectin, and pyrantel chewable tablets)

Elanco Confirms Date and Conference Call for Second Quarter 2026 Financial Results Announcement

Elanco To Launch Elanco Ventures With $25 Million Multi-Year Commitment To Accelerate Innovation in Animal Health

Elanco to Launch Elanco Ventures with $25 Million Multi-Year Commitment to Accelerate Innovation in Animal Health

Elanco Announces USDA Approval of TruCan Ultra Lyme-L4, the First and Only 1/2 mL Combination Vaccine for Lyme and Leptospirosis for Dogs

Elanco Announces USDA Approval of TruCan™ Ultra Lyme-L4, the First and Only 1/2 mL Combination Vaccine for Lyme and Leptospirosis for Dogs

Elanco Animal Health Commits to Supporting U.S. Livestock Producers and Pet Owners in Fight Against New World Screwworm

New Research Reveals Pet Spending as a "Protected Budget Item" for Owners, Fueling Industry Resilience

Elanco Launches Befrena™ (tirnovetmab), New Anti-IL-31 Monoclonal Antibody, a Breakthrough Addition to the $1.3 Billion U.S. Canine Dermatology Market

Elanco Animal Health Reports First Quarter 2026 Results

Elanco's Negasunt™ Powder (Coumaphos, Propoxur, Sulfanilamide Topical Powder) and Tanidil™ (Coumaphos, Propoxur) Receive Emergency Authorization for Use Against New World Screwworm in Livestock

/C O R R E C T I O N -- Elanco Animal Health/

Elanco Confirms Date and Conference Call for First Quarter 2026 Financial Results Announcement

Elanco Launches Advantage™ Collar for Dogs with Four Months of Continuous Protection from Fleas, Ticks and Mosquitoes*

Amlan International and Elanco Collaborate on Japanese Educational Seminars Focused on Calf Health

Elanco Animal Health Reports Fourth Quarter and Full Year 2025 Results

Elanco Australia Receives APVMA Approval for Advocate™ Ultra Chew: The Broadest Spectrum Parasite Protection* for Dogs in Australia

Elanco to Participate in Upcoming Investor Conferences

Elanco Announces Updates to Board of Directors

Elanco Confirms Date and Conference Call for Fourth Quarter and Full Year 2025 Financial Results Announcement

Elanco to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Elanco Receives USDA Approval for Befrena™ (tirnovetmab), a New Anti-IL31 Monoclonal Antibody Injection Targeting Canine Allergic and Atopic Dermatitis

Elanco's Credelio Quattro™-CA1 (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets) Receives First FDA Conditional Approval for Treatment of New World Screwworm in Dogs

Elanco Announces Investment in U.S. Manufacturing and R&D, Driven by Tax, Tariff and Regulatory Clarity

Elanco Animal Health Incorporated : Announces Full USDA Approval of CPMA (Now Trutect™) the First-and-Only Treatment for Deadly Canine Parvovirus

Elanco Investor Day Defines New Era as Sustainable Growth Company

Elanco executive appointed as Neurizon's Board Observer

Elanco's Credelio™ CAT (lotilaner) Receives First FDA Emergency Use Authorization (EUA) for Treatment of New World Screwworm (NWS) in Cats

Elanco to Participate in the Upcoming Investor Conferences

Alloy Partners Launches OneHealth Studio to Create Startups at the Convergence of Animal, Plant and Human Health

Elanco Animal Health Reports Third Quarter 2025 Results

Elanco Announces Expansion of Credelio Quattro™ (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets) and Credelio™ (lotilaner) Labels, Offering Protection Against Lyme Disease and an Emerging Tick Species

Elanco's Credelio™ (lotilaner) Receives First Ever FDA Emergency Use Authorization (EUA) against New World Screwworm (NWS) in Dogs

Elanco to Host Investor Day on December 9

Elanco Confirms Date and Conference Call for Third Quarter 2025 Financial Results Announcement

Elanco Announces FDA Approves Improved Zenrelia™ (ilunocitinib tablets) Label, Removing Vaccine-Induced Disease Language

Elanco Innovation Builds Momentum, Credelio Quattro™ (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets) Reaches Blockbuster Status

Splenda® Joins Elanco and HATCH to Support 'Nutrition Secure Indianapolis' to Strengthen Family Health Through Nutrition and Education

Elanco Animal Health Set to Join S&P MidCap 400; Sarepta Therapeutics to Join S&P SmallCap 600